Yuhan Corp.'s new cancer drug, Leclaza, swiftly wins reimbursement listing for its use as a first-line treatment.

Following success with its second-line treatment, Leclaza received reimbursement for the first-line treatment within just six months of approval. The second-line treatment alone has generated quarterly sales of 6 billion won and continues to perform well. Similar to the success of the anticancer immunotherapy Keytruda after its reimbursement expansion , Leclaza is also anticipated to considerably benefit from its inclusion as first-line treatment.

Recently, the Ministry of Health and Welfare (MOHW) held a meeting of the Health Insurance Policy Deliberation Committee and approved